- Home
- CYCU vs TXMD Comparison
CYCU vs TXMD Comparison
Compare CYCU & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCU
- TXMD
- Stock Information
- Founded
- CYCU N/A
- TXMD 2008
- Country
- CYCU United States
- TXMD United States
- Employees
- CYCU N/A
- TXMD N/A
- Industry
- CYCU
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- CYCU
- TXMD Health Care
- Exchange
- CYCU Nasdaq
- TXMD Nasdaq
- Market Cap
- CYCU 13.1M
- TXMD 12.7M
- IPO Year
- CYCU N/A
- TXMD N/A
- Fundamental
- Price
- CYCU $0.30
- TXMD $1.17
- Analyst Decision
- CYCU
- TXMD
- Analyst Count
- CYCU 0
- TXMD 0
- Target Price
- CYCU N/A
- TXMD N/A
- AVG Volume (30 Days)
- CYCU 3.5M
- TXMD 24.2K
- Earning Date
- CYCU 08-13-2025
- TXMD 08-12-2025
- Dividend Yield
- CYCU N/A
- TXMD N/A
- EPS Growth
- CYCU N/A
- TXMD N/A
- EPS
- CYCU N/A
- TXMD N/A
- Revenue
- CYCU $17,398,680.00
- TXMD $2,559,000.00
- Revenue This Year
- CYCU N/A
- TXMD $427.09
- Revenue Next Year
- CYCU N/A
- TXMD N/A
- P/E Ratio
- CYCU N/A
- TXMD N/A
- Revenue Growth
- CYCU N/A
- TXMD 156.93
- 52 Week Low
- CYCU $0.26
- TXMD $0.70
- 52 Week High
- CYCU $10.99
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- CYCU N/A
- TXMD 54.93
- Support Level
- CYCU N/A
- TXMD $1.06
- Resistance Level
- CYCU N/A
- TXMD $1.12
- Average True Range (ATR)
- CYCU 0.00
- TXMD 0.04
- MACD
- CYCU 0.00
- TXMD 0.01
- Stochastic Oscillator
- CYCU 0.00
- TXMD 73.27
About CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.